Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 7/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | TYMS | P04818 | 1/20 | 0.51 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.49 |
| ▸ | DHFR | P00374 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.47 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10506664 | 0.88 | PNP (0.60) | PNPADORA2AADORA1TYMSHPRT1 | |
| SCHEMBL10506827 | 0.88 | PNP (0.60) | PNPADORA2AADORA1TYMSHPRT1 | |
| SCHEMBL10506260 | 0.87 | PNP (0.58) | PNPADORA2AADORA1TYMSHPRT1 | |
| SCHEMBL27851218 | 0.87 | PNP (0.62) | PNPADORA2AADORA1HPRT1DHFR | |
| SCHEMBL10506494 | 0.87 | PNP (0.58) | PNPTYMSHPRT1DHFRXDH | |
| SCHEMBL9798201 | 0.87 | PNP (0.58) | PNPADORA2AADORA1HPRT1PDE7A | |
| SCHEMBL6359274 | 0.86 | PNP (1.00) | PNPTYMSDHFRXDHTLR7 | |
| SCHEMBL7663884 | 0.84 | PNP (0.76) | PNPTYMSDHFRXDHTLR7 | |
| SCHEMBL10508294 | 0.84 | TYMS (0.56) | PNPTYMSHPRT1XDHTLR7 | |
| SCHEMBL10506462 | 0.84 | PNP (0.58) | PNPTYMSHPRT1XDHPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012145794-A1 | METHOD OF DETERMINING RESPONSE TO TREATMENT WITH IMMUNOMODULATORY COMPOSITION | THE UNIVERSITY OF SYDNEY (AU) | 2012-11-01 | — | — | WO | claimed |
| EP-2443257-A1 | METHOD OF DETERMINING RESPONSE TO TREATMENT WITH IMMUNOMODULATORY COMPOSITION | The University Of Sydney (AU) | 2012-04-25 | — | — | EP | claimed |
| WO-2011146985-A1 | METHOD OF DETERMINING RESPONSE TO TREATMENT WITH IMMUNOMODULATORY COMPOSITION | THE UNIVERSITY OF SYDNEY (AU) | 2011-12-01 | — | — | WO | claimed |
| WO-2010144946-A1 | METHOD OF DETERMINING RESPONSE TO TREATMENT WITH IMMUNOMODULATORY COMPOSITION | THE UNIVERSITY OF SYDNEY (AU) | 2010-12-23 | — | — | WO | claimed |
| US-20100316608-A1 | Method of Determining A Response To Treatment With Immunomodulatory Composition | WESTERN SYDNEY LOCAL HEALTH DISTRICT (AU) | 2010-12-16 | — | — | US | claimed |
| US-11986480-B2 | Heterocyclic compound | TOHOKU UNIVERSITY (JP) | 2024-05-21 | — | — | US | disclosed |
| EP-4319773-A1 | MODIFICATION OF EPOR-ENCODING NUCLEIC ACIDS | Ensoma, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023150393-A2 | INHIBITOR-RESISTANT MGMT MODIFICATIONS AND MODIFICATION OF MGMT-ENCODING NUCLEIC ACIDS | ENSOMA, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20200163970-A1 | HETEROCYCLIC COMPOUND | TOHOKU UNIVERSITY (JP) | 2020-05-28 | — | — | US | disclosed |
| WO-2012145794-A1 | METHOD OF DETERMINING RESPONSE TO TREATMENT WITH IMMUNOMODULATORY COMPOSITION | THE UNIVERSITY OF SYDNEY (AU) | 2012-11-01 | — | — | WO | disclosed |
| US-20120183497-A1 | Method of Determining Response to Treatment with Immunomodulatory Composition | GEORGE JACOB (AU) | 2012-07-19 | — | — | US | disclosed |
| EP-2443257-A1 | METHOD OF DETERMINING RESPONSE TO TREATMENT WITH IMMUNOMODULATORY COMPOSITION | The University Of Sydney (AU) | 2012-04-25 | — | — | EP | disclosed |
| EP-0775142-B1 | SUBSTITUTED O6 -BENZYLGUANINES | US HEALTH (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1142893-A1 | Substituted O6-benzylguanines and 6(4)-benzyloxypyrimidines | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0775142-A1 | SUBSTITUTED O6 -BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004281-A1 | SUBSTITUTED O6-BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-02-15 | — | — | WO | disclosed |
| US-4874862-A | Process for preparing guanine derivatives | WARNER-LAMBERT COMPANY (US) | 1989-10-17 | — | — | US | disclosed |
| EP-0156559-B1 | 8-SUBSTITUTED GUANINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1989-08-02 | — | — | EP | disclosed |
| US-4748177-A | Guanine derivatives | WARNER-LAMBERT COMPANY (US) | 1988-05-31 | — | — | US | disclosed |
| EP-0156559-A2 | 8-Substituted guanine derivatives | WARNER-LAMBERT COMPANY (US) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163970-A1 | HETEROCYCLIC COMPOUND | SQSTM1, BECN1, ATG7 | PNP 4447/4885ADORA2A 4202/4885ADORA1 4489/4885 |
| US-11986480-B2 | Heterocyclic compound | SQSTM1, BECN1, ATG7 | PNP 4447/4885ADORA2A 4202/4885ADORA1 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.